Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

ABSTRACT:

Background

The comparative safety and efficacy of the biologics currently approved for asthma are unclear.

Objective

We compared the safety and efficacy of mepolizumab, benralizumab, and dupilumab in individuals with severe eosinophilic asthma.

Methods

We performed a systematic review of peer-reviewed literature published 2000 to 2021. We studied Bayesian network meta-analyses of exacerbation rates, prebronchodilator FEV₁, the Asthma Control Questionnaire, and serious adverse events in individuals with eosinophilic asthma.

Results

Eight randomized clinical trials (n = 6461) were identified. We found in individuals with eosinophils ≥300 cells/μL the following: in reducing exacerbation rates compared to placebo: dupilumab (risk ratio [RR], 0.32; 95% cr

SUBMITTER: Akenroye A 

PROVIDER: S-EPMC9643621 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature